Wegovy (semaglutide), a GLP-1 medication, and other GLP-1 receptor agonists may improve some cholesterol measurements. The effect is usually modest, however, and it is not the same for every medicine or every person.
That distinction matters. A better lipid panel may be one benefit of treatment, but a GLP-1 medication is not automatically a substitute for a statin or another cholesterol-lowering medicine.
What May Change on Your Lipid Panel
A lipid panel usually includes LDL cholesterol, HDL cholesterol, triglycerides, and total cholesterol. These numbers have different meanings and should be interpreted alongside factors such as blood pressure, diabetes, smoking, family history, and previous heart disease.
LDL cholesterol
LDL is often called “bad” cholesterol because it can build up in artery walls. Lower is generally better, but the right goal depends on a person's overall cardiovascular risk.
A 2025 meta-analysis of placebo-controlled randomized trials found that GLP-1 receptor agonists lowered LDL by an average of about 2.9 mg/dL. That is a modest average change, not a guarantee for an individual patient.
Total cholesterol
The same meta-analysis found an average reduction in total cholesterol of about 7 mg/dL. Total cholesterol is only one part of the picture; LDL and overall cardiovascular risk are more useful when treatment decisions are made.
Triglycerides
Triglycerides are a type of fat that stores excess energy. High levels can add to cardiovascular risk, especially alongside high LDL or low HDL.
Some individual semaglutide trials have reported lower triglycerides. But across the trials in the 2025 meta-analysis, the average triglyceride reduction was not statistically significant. The evidence therefore does not support assuming a consistent class-wide reduction.
HDL cholesterol
HDL is often called “good” cholesterol because it helps transport cholesterol away from artery walls. Still, the American Heart Association notes that HDL is not a stand-alone treatment target.
The 2025 meta-analysis did not find a significant HDL increase with GLP-1 receptor agonists, so a routine class-wide increase is not supported.
Why Results Differ Between Studies
The answer depends on the medication, dose, study population, starting lipid levels, weight change, diet, and use of other treatments such as statins.
In exploratory analyses of the STEP 1 and STEP 4 trials, semaglutide 2.4 mg—a GLP-1 medication—improved LDL, non-HDL cholesterol, and triglycerides in adults with overweight or obesity without diabetes. Greater weight loss was generally associated with greater improvement in cardiometabolic risk factors. The analyses also suggested that some changes, particularly in non-HDL cholesterol, might not be explained by weight loss alone.
Those findings are useful, but they do not prove that every lipid change is a direct drug effect. The STEP analyses were exploratory, some outcomes were post hoc, and the authors cautioned against overinterpreting comparisons between people who lost similar amounts of weight.
Cholesterol Numbers and Heart Protection Are Not the Same Question
A medicine can have cardiovascular benefits that are not fully explained by a change in LDL, HDL, or triglycerides. It is also unsafe to assume that a small change in any one marker automatically produces a specific reduction in heart attack or stroke risk.
The SELECT evidence is specific to a particular medicine and population. In the SELECT cardiovascular-outcomes trial, semaglutide 2.4 mg reduced cardiovascular death, nonfatal heart attack, or nonfatal stroke from 8.0% with placebo to 6.5% with semaglutide over an average follow-up of about 40 months. Participants were age 45 or older, had established cardiovascular disease and overweight or obesity, and did not have diabetes.
Based on that evidence, the FDA approved Wegovy to reduce those cardiovascular risks in adults with cardiovascular disease and overweight or obesity. That indication should not be generalized to every GLP-1 medicine or every person who takes one.
For more context, see GLP-1 medications and heart health.
If You Already Take a Statin
Do not stop or reduce a statin because you started semaglutide or another GLP-1 medication. The drugs have different purposes, and the modest average LDL change seen with GLP-1 receptor agonists does not make them interchangeable with established cholesterol-lowering therapy.
In SELECT, participants received semaglutide or placebo in addition to standard care, including cholesterol and blood-pressure management. Talk with the clinician managing your medications before making a change.
Lifestyle Still Matters
Medication does not replace habits that support cardiovascular health. The American Heart Association recommends reducing saturated and trans fat while emphasizing vegetables, fruits, whole grains, legumes, nuts, fiber, and lean proteins.
Helpful priorities include:
- Reduce saturated and trans fat.
- Add fiber-rich foods such as oats, beans, lentils, fruits, and vegetables.
- Choose physical activity you can sustain.
- Avoid tobacco and secondhand smoke.
- Limit excess alcohol, which can raise triglycerides.
If appetite suppression or gastrointestinal side effects make it difficult to eat a varied diet, ask your care team or a registered dietitian for individualized guidance.
When Should Cholesterol Be Checked?
There is no universal rule to obtain a lipid panel before starting a GLP-1 medication or exactly three months afterward. Testing should be based on your age, cardiovascular risk, existing cholesterol treatment, and clinician's plan.
For general screening, the American Heart Association says every five years works well for most adults beginning at age 19, while people with additional risk factors may need testing more often. If a statin or another lipid-lowering treatment is started or changed, follow the monitoring schedule given by the prescriber.
The Bottom Line
GLP-1 receptor agonists may modestly lower LDL and total cholesterol on average. Evidence for a consistent class-wide reduction in triglycerides or increase in HDL is less certain. Individual results can differ substantially.
Semaglutide, a GLP-1 medication, has also reduced major cardiovascular events in a clearly defined high-risk population—but that benefit should not be attributed solely to changes on a lipid panel or generalized to every drug in the category.
Use follow-up results as one part of a broader conversation about cardiovascular risk. Keep taking prescribed cholesterol medication unless the prescriber advises a change.
This article is for informational purposes only and does not replace medical advice. Talk with a qualified healthcare professional about cholesterol targets, testing, and medication changes.
